NASDAQ:JSPR

Jasper Therapeutics - JSPR Stock Forecast, Price & News

$0.56

-0.02 (-3.43%)

(As of 12/7/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.56
▼
$0.61
50-Day Range: $0.56
▼
$0.89
52-Week Range: $0.56
▼
$10.69

Volume: 14,635 shs
Average Volume: 62,832 shs
Market Capitalization: $21.37 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.25

Jasper Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,188.4% Upside
$7.25 Price Target
Short Interest: Healthy
0.88% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.34) to ($1.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

548th out of 1,027 stocks

Biological Products, Except Diagnostic Industry

91st out of 171 stocks

3.5

Analyst's Opinion

Consensus Rating
Jasper Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.25, Jasper Therapeutics has a forecasted upside of 1,188.4% from its current price of $0.56.
Amount of Analyst Coverage
Jasper Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.88% of the float of Jasper Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Jasper Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Jasper Therapeutics has recently increased by 37.62%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Jasper Therapeutics does not currently pay a dividend.
Dividend Growth
Jasper Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for JSPR.

0.6

News and Social Media Coverage

MarketBeat Follows
1 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
22.00% of the stock of Jasper Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
71.83% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Jasper Therapeutics are expected to decrease in the coming year, from ($1.34) to ($1.42) per share.
Price to Book Value per Share Ratio
Jasper Therapeutics has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Jasper Therapeutics (NASDAQ:JSPR) Stock

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JSPR Stock News Headlines

November 10, 2022 | finance.yahoo.com

Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

September 26, 2022 | finance.yahoo.com

Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting

December 8, 2022 | Vantage Point (Ad)

Defy EOY Volatility with Artificial Intelligence

Have you ever heard if you are having issues in your trading, it could be that it's not you - it really is the market? Well, you’re in control. You can sit on the sideline when it feels right, or better yet anticipate massive trend reversals with A.I. You’ve got to see it live to understand it.

September 23, 2022 | finance.yahoo.com

Jasper Therapeutics to Present at Upcoming Conferences

September 17, 2022 | marketwatch.com

Jasper Therapeutics Shares Jump Premarket on JSP191 Fast-Track Status >JSPR

September 15, 2022 | msn.com

Jasper Shares Climb As FDA Grants Fast Track Status To Immunodeficiency Disease Candidate

September 15, 2022 | finance.yahoo.com

Jasper Therapeutics Announces FDA Fast Track Designation for JSP191, a novel monoclonal antibody targeting CD117, in the treatment of patients with severe combined immunodeficiency (SCID) undergoing allogeneic hematopoietic stem cell transplant

August 12, 2022 | finance.yahoo.com

Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

December 8, 2022 | Vantage Point (Ad)

Defy EOY Volatility with Artificial Intelligence

July 15, 2022 | nasdaq.com

All You Need to Know About Jasper Therapeutics, Inc. (JSPR) Rating Upgrade to Buy

June 23, 2022 | finance.yahoo.com

Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

June 20, 2022 | finance.yahoo.com

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

June 18, 2022 | seekingalpha.com

Bone Biologics, Akero top healthcare gainers; AC Immune, Arcellx lead losers' pack

June 7, 2022 | finance.yahoo.com

Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference

June 6, 2022 | finance.yahoo.com

Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022

May 17, 2022 | finance.yahoo.com

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

May 12, 2022 | finance.yahoo.com

Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

April 28, 2022 | finance.yahoo.com

Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA Meeting

April 26, 2022 | finance.yahoo.com

Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation

April 22, 2022 | finance.yahoo.com

Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies

March 31, 2022 | finance.yahoo.com

Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual Meeting

March 25, 2022 | finance.yahoo.com

Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 21, 2022 | seekingalpha.com

Jasper Therapeutics creates new position for medical and operations chief

March 21, 2022 | finance.yahoo.com

Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team

March 20, 2022 | benzinga.com

Jasper Therapeutics FY21 Net Loss $30.6M vs Net Loss $31.7M In FY20

March 18, 2022 | seekingalpha.com

Jasper Therapeutics GAAP EPS of -$2.69 misses by $0.46

March 18, 2022 | finance.yahoo.com

Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive JSPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JSPR Company Calendar

Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/17/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:JSPR
CUSIP: N/A
CIK: 1788028
Web: jaspertherapeutics.com
Phone: 650-549-1400
Fax: N/A
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.25
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +1,188.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -72.43%
Return on Assets: -58.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.06
Quick Ratio: 7.06

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.84 per share
Price / Book: 0.31

Miscellaneous

Outstanding Shares: 37,984,000
Free Float: 29,628,000
Market Cap: $21.37 million
Optionable: Not Optionable
Beta: 1.00

Key Executives

Dr. Judith Anne Shizuru M.D. (Age 65)
Ph.D., Co-Founder, Chair of Scientific Advisory Board & Director
Comp: $260.77k

Mr. Jeetinder Singh Mahal M.B.A. (Age 49)
CFO, COO & Corp. Sec.
Comp: $461.12k

Dr. Kevin N. Heller M.D. (Age 51)
Exec. VP of R&D
Comp: $617.99k

Mr. Ronald A. Martell (Age 60)
Pres, CEO & Director

Dr. Susan Prohaska Ph.D.
Co-Founder and VP of Operations & Program Management

Dr. Carol Zoltowski (Age 72)
Sr. VP of Regulatory Affairs & Quality

Dr. Wendy Pang M.D.
Ph.D., Sr. VP of Research & Translational Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

JSPR Stock - Frequently Asked Questions

Should I buy or sell Jasper Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jasper Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JSPR shares.
View JSPR analyst ratings or view top-rated stocks.
What is Jasper Therapeutics' stock price forecast for 2023?: 4 Wall Street analysts have issued 1 year target prices for Jasper Therapeutics' stock. Their JSPR share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.25 in the next year. This suggests a possible upside of 1,188.4% from the stock's current price.
View analysts price targets for JSPR or view top-rated stocks among Wall Street analysts.
How have JSPR shares performed in 2022?: Jasper Therapeutics' stock was trading at $7.85 on January 1st, 2022. Since then, JSPR shares have decreased by 92.8% and is now trading at $0.5627.
View the best growth stocks for 2022 here.
Are investors shorting Jasper Therapeutics?: Jasper Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 110,100 shares, an increase of 37.6% from the October 31st total of 80,000 shares. Based on an average daily trading volume, of 70,300 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.9% of the company's stock are short sold.
View Jasper Therapeutics' Short Interest.

When is Jasper Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, March 17th 2023.
View our JSPR earnings forecast.
What is Jasper Therapeutics' stock symbol?: Jasper Therapeutics trades on the NASDAQ under the ticker symbol "JSPR."
Who are Jasper Therapeutics' major shareholders?: Jasper Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (8.45%), Vanguard Group Inc. (1.45%), Fernwood Investment Management LLC (0.81%), UBS Group AG (0.51%) and Forefront Analytics LLC (0.33%).
View institutional ownership trends.
How do I buy shares of Jasper Therapeutics?: Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Jasper Therapeutics' stock price today?: One share of JSPR stock can currently be purchased for approximately $0.56.
How much money does Jasper Therapeutics make?: Jasper Therapeutics (NASDAQ:JSPR) has a market capitalization of $21.37 million.
How can I contact Jasper Therapeutics?: Jasper Therapeutics' mailing address is 1177 AVENUE OF THE AMERICAS FL 40, NEW YORK NY, 10036. The official website for the company is jaspertherapeutics.com. The company can be reached via phone at 650-549-1400 or via email at jmullaly@lifesciadvisors.com.

This page (NASDAQ:JSPR) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial